Over the past year, analysts covering Reinsurance Group of America have steadily increased their outlook on the company’s shares. One year ago, the consensus price target stood at $219.63; today it sits near $237.50, an increase of $17.87 that underscores rising optimism. Major Wall Street firms, including Wells Fargo, have lifted their individual targets—the latter to $238—reflecting expectations for stronger underwriting results, favorable mortality trends and continued margin expansion in RGA’s life and health reinsurance operations.

Breaking down the trajectory further, the average analyst projection three months ago was $228.25, and it has since risen by $9.25. This quarter-over-quarter uptick signals growing conviction in RGA’s ability to leverage its diversified book of business, from U.S. traditional life reinsurance to international financial solutions. The Zacks Rank system, which emphasizes earnings estimate revisions, has highlighted RGA as a top value pick despite the company not having the perfect combination of factors for an imminent earnings beat.

RGA will report fourth-quarter earnings on February 5, with a conference call scheduled for February 6. Analysts currently forecast adjusted EPS of $5.86 and revenue near $6.25 billion, reflecting upward revisions of 0.6% in the past 30 days. Key valuation metrics include a P/E ratio of 15.44, a price/sales ratio of 0.60 and an enterprise value/operating cash flow ratio of 2.98. With a debt/equity ratio of 0.44 and an earnings yield of 6.48%, investors will focus on management’s commentary regarding reserve development, capital deployment plans and reinsurance rate trends to gauge whether the actual results will exceed these estimates.